Man­u­fac­tur­ing roundup: Qual­i­ty is­sues at Sun Phar­ma plant in In­dia; Forge se­cures gene ther­a­py man­u­fac­tur­ing con­tract

The FDA has re­vealed fur­ther is­sues at a Sun Phar­ma man­u­fac­tur­ing fa­cil­i­ty in In­dia.

Last month, Sun Phar­ma an­nounced it was paus­ing pro­duc­tion at one of its plants in Mo­hali, In­dia, af­ter fac­ing scruti­ny by US reg­u­la­tors over nec­es­sary cor­rec­tive work. US reg­u­la­tors ul­ti­mate­ly con­veyed to the com­pa­ny that it needs to take cor­rec­tive ac­tions at the man­u­fac­tur­ing fa­cil­i­ty be­fore it can ship any prod­ucts to the US.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN